Clinical Trials in the EU / 2025-524218-27-00
Ended
Phase I
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.
2025-524218-27-00 · tracked via the Priya Life Science EU tracker
Condition studied
treatment of myasthenia gravis
Eligibility
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-524218-27-00 on CTIS ↗ ← All trials in the EU